Overview

• Since early 2025 the patient has maintained remission on risperidone followed by olanzapine but experienced prompt relapse whenever doses were skipped.
• A July 2025 AME Case Reports paper by Jing Yan and Dafang Ouyang has reignited clinical interest in dopamine dysfunction as a root cause of PGAD.
• Her diagnosis was confirmed only after exhaustive neurological tests ruled out epilepsy and structural abnormalities.
• Persistent genital arousal disorder affects an estimated 0.6 to 3 percent of people—primarily women—and involves intrusive genital sensations without sexual desire that disrupt daily life.
• The case highlights dopamine-blocking antipsychotics as a promising targeted therapy and underscores the need for long-term management of this underdiagnosed disorder.